Praluent Patent Update

[anonymous]

https://www.bloomberg.com/news/arti...-cholesterol-drug-repatha-are-valid-jury-says

https://in.reuters.com/article/amgen-patent-idINKCN1QE2K7

 

[anonymous]

RIP Praluent. It was fun while it lasted.
Should we bury or cremate this old dog?
Medical community always thought we had the ugliest dog at the dog show.

Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies

 

[anonymous]

Our data is so strong this will effect nothing. Just wait! This drug is gonna be huuuuge

 

[anonymous]

When the company attempts to make us feel more confident and calm I feel the EXACT opposite.

 

[Karma kicks sanofi ass]

Sanofi fucks the American people, they steal patents, do international bribes, treat their reps like shit (remember Zaltrap?)

Goes around etc etc etc .

 

[anonymous]

Sanofi fucks the American people, they steal patents, do international bribes, treat their reps like shit (remember Zaltrap?)

Goes around etc etc etc .

Someone's having a bad day

 

[anonymous]

Diabetes and cardiology division, it’s time to wake up. Sanofi’s growth focus is in rare blood disorder, immunology and oncology - as stated in Q4 earnings call. It is no longer looking to grow or expand the diabetes or cardiovascular portfolio, at least in house. Of the 13 in house pipeline projects killed off in 2018, 7 were in diabetes and cardiology. Further more they are “accelerating proof of concept” projects in all other therapeutic areas excluding diabetes and cardiology with a heavy emphasis on oncology.


See full Q4/YE presentation in link below which provides solid insight to company direction.


https://www.sanofi.com/-/media/Proj...hash=75B2F14399D5953B6836F62157D27605B0A8BE0A

 

[anonymous]

Just heard cvs Caremark bumped Praluent off the formulary leaving Rapatha as sole preferred pcsk9.
I thought coverage would improve with the price drop. Oh well, at least patients have access to pcsk9 therapy. Sanofi wins second place. Wonk wonk wonk.

 

[anonymous]

Ouch! If true...that hurts. I guess CV is no better off than us in Diabetes.

 

[anonymous]

Just heard cvs Caremark bumped Praluent off the formulary leaving Rapatha as sole preferred pcsk9.
I thought coverage would improve with the price drop. Oh well, at least patients have access to pcsk9 therapy. Sanofi wins second place. Wonk wonk wonk.

that happened last year dump fuck, keep up with current events

 

[anonymous]

Just heard cvs Caremark bumped Praluent off the formulary leaving Rapatha as sole preferred pcsk9.
I thought coverage would improve with the price drop. Oh well, at least patients have access to pcsk9 therapy. Sanofi wins second place. Wonk wonk wonk.

They should have told us sooner.

 

[anonymous]

Sanofi fucks the American people, they steal patents, do international bribes, treat their reps like shit (remember Zaltrap?)

Goes around etc etc etc .

Other than that they are a great company.